UNSPSC 51112609: Neptamustine or pentamustine

This classification denotes a nitrosourea compound, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VB67O9FBGM. European Medicines Agency schedules Neptamustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09201MIG. Neptamustine generally arises in the molecular formula C8H16CLN3O2.

The term NEPTAMUSTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, no. 6, 1983, list 23.) NEPTAMUSTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Neptamustine or pentamustine bears US NLM identifiers UMLS ID C1882315 and NCI Concept Code C66341. SMILES: CLCCN(N=O)C(=O)NCC(C)(C)C.

UNSPSC 51112609 Neptamustine or pentamustine is a Commodity code that nominally covers specific chemotherapy agents, but recent state and local procurement activity shows minimal direct demand for these particular pharmaceuticals. The single recent opportunity in the dataset is a Texas Health and Human Services Commission Request for Information (RFI) issued April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program — a market intelligence exercise focused on pharmacy benefit management and direct contracting models rather than procurement of specific drug compounds. The RFI targets vendors with experience in direct contracting relationships between state agencies and pharmaceutical manufacturers, negotiated net pricing without rebates, and value-based or outcomes-based agreements, but does not specify demand for neptamustine or pentamustine as line items.

The geographic spread and issuing-body mix are not meaningfully characterized by this record. The sole recent opportunity originates from Texas HHS, a state health agency, but the RFI's exploratory nature and lack of product-specific targeting limits visibility into whether this code will drive actual pharmaceutical procurement going forward. The RFI documentation does not identify award values, budget ranges, or formal evaluation timelines, as the state is in an early information-gathering phase before issuing a formal RFP with established financial and temporal parameters. For vendors pursuing state and local pharmaceutical supply contracts, this code shows little active market signal at present; focus should remain on broader pharmaceutical distribution codes and emerging state pharmacy benefit restructuring initiatives rather than neptamustine or pentamustine procurement specifically.